Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with PMF, PPV-MF or PET-MF as confirmed by bone marrow biopsy
Discontinuation of all drugs used to treat underlying MF disease at least 14 days prior to baseline visit
INR \<= 1.5 or PTT value \< 1.5 x upper limit of normal (ULN) at study entry
Hemoglobin level at least 6.5 g/dL at Screening visit
Willingness to be transfused to treat low hemoglobin levels
You may not be if
Females who are pregnant, unable to comply with birth control use to avoid becoming pregnant or breastfeeding
Males who cannot comply with birth control use to avoid fathering a child
Platelet count \< 50 x10\^9/L or absolute neutrophil count (ANC) \< 1 x10\^9/L at the Screening visit
Inadequate liver or renal function; Intracranial bleeds or invasive malignancy over the previous 2 years - international normalized ratio (INR) laboratory values cannot be \> 1.5 x upper limit of normal at study entry.
Clareo Health | Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
